Sikander Ailawadhi
SWOG Cancer Research Network · Mayo Clinic
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Sikander Ailawadhi as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:19 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT05561387 · Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable TreatmentSWOG Cancer Research Network · recruiting · Plasma Cell Myeloma · principal investigator
- Ph2NCT04840602 · Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaNational Cancer Institute (NCI) · recruiting · Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia · principal investigator
- N/ANCT04630431 · Understanding Challenges, Behavioral Patterns, and Preferences Toward Participation in Clinical Trials in Minority Patient Populations: Development of a Personalized Clinical Trial Educational Platform to Increase Participation in Clinical Trials Among Underserved Cancer PatientsMayo Clinic · terminated · Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm · principal investigator
- Ph2NCT04230304 · Daratumumab and Ibrutinib for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia, DIRECT StudyMayo Clinic · terminated · Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Recurrent Small Lymphocytic Lymphoma · principal investigator
- Ph2NCT03713294 · Dexamethasone, Elotuzumab, and Pomalidomide in Treating Patients With Refractory Multiple MyelomaMayo Clinic · completed · Refractory Plasma Cell Myeloma · principal investigator
- Ph2NCT03477539 · Daratumumab in Treating Transplant-Eligible Patients With Multiple MyelomaMayo Clinic · completed · Plasma Cell Myeloma · principal investigator
- Ph1NCT03015792 · Ibrutinib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Ineligible for TransplantMayo Clinic · terminated · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
- Ph1NCT02697344 · Gossypol Acetic Acid With Lenalidomide and Dexamethasone in Treating Patients With Relapsed Symptomatic Multiple MyelomaMayo Clinic · completed · Recurrent Plasma Cell Myeloma · principal investigator
- Ph2NCT02649387 · Ibrutinib in Treating Minimal Residual Disease in Patients With Chronic Lymphocytic Leukemia After Front-Line TherapyMayo Clinic · completed · Stage I Chronic Lymphocytic Leukemia, Stage II Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia · principal investigator
- Ph2NCT01903811 · S1304, Carfilzomib and Dexamethasone for Treating Patients With Relapsed or Refractory MyelomaSWOG Cancer Research Network · completed · Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:19 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI DAWN HERSHMAN, PRIMO N. LARA · fiscal years 2014 to 2026
- Southwest Oncology Group Treatment GrantU10CA032102 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI CHARLES D. BLANKE · fiscal years 1985 to 2013Named on NCT01903811
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 08:19 UTC. The ranking covers the 200 most relevant of 32 PubMed records, and a shared surname and initials can bring in a namesake. All 32 on PubMed
- Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma.N Engl J Med · 2023686 citationsRCR 61.1
- 150 citationsRCR 4.1
- Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study.Ann Intern Med · 2018122 citationsRCR 4.7
- Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.Lancet Haematol · 2021113 citationsRCR 6.5
- 78 citationsRCR 9.1
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial.Lancet Haematol · 201861 citationsRCR 2.0
- Phase I study of the anti-FcRH5 antibody-drug conjugate DFRF4539A in relapsed or refractory multiple myeloma.Blood Cancer J · 201961 citationsRCR 2.0
- A Phase I Study to Assess the Safety and Pharmacokinetics of Single-agent Lorvotuzumab Mertansine (IMGN901) in Patients with Relapsed and/or Refractory CD-56-positive Multiple Myeloma.Clin Lymphoma Myeloma Leuk · 201959 citationsRCR 2.1
- 57 citationsRCR 1.9
- 52 citationsRCR 1.7